Interventional oncology: New options for interstitial treatments and intravascular approaches: Targeting tumor metabolism via a loco-regional approach: A new therapy against liver cancer

Eleni Liapi, Jean Francois Geschwind

Research output: Contribution to journalArticlepeer-review

Abstract

Recent research in tumor metabolism has uncovered cancer-cell-specific pathways that cancer cells depend on for energy production. 3-Bromopyruvate (3-BrPA), a specific alkylating agent and potent ATP inhibitor, has been shown both in vitro and in vivo to disrupt some of these cancer-specific metabolic pathways, thereby leading to the demise of the cancer cells through apoptosis. 3-BrPA has been successfully tested in animal models of liver cancer. For optimal results, 3-BrPA can be delivered intra-arterially, with minimal toxicity to the surrounding hepatic parenchyma. In the era of development of drugs with lower toxicity for the treatment of liver cancer, inhibition of cancer metabolism with 3-BrPA appears to be a very attractive potent novel therapeutic option.

Original languageEnglish (US)
Pages (from-to)405-406
Number of pages2
JournalJournal of Hepato-Biliary-Pancreatic Sciences
Volume17
Issue number4
DOIs
StatePublished - Jul 2010

Keywords

  • 3-Bromopyruvate
  • PET imaging
  • Tumor metabolism
  • Warburg effect

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Interventional oncology: New options for interstitial treatments and intravascular approaches: Targeting tumor metabolism via a loco-regional approach: A new therapy against liver cancer'. Together they form a unique fingerprint.

Cite this